GM Backed Momenta Set for Hong Kong Debut After $752 Million IPO The highly anticipated initial public offering (IPO) of Momenta, a gene editing company backed by General Motors (GM), is set to make its debut in Hong Kong with a valuation of $752 million.
This significant investment underscores the growing interest in biotechnology and gene editing technologies, which are revolutionizing the healthcare industry.
The Science Behind Momenta: Gene Editing Technology Momenta's technology is based on CRISPR Cas9 gene editing, allowing for precise modifications to the human genome.